Neratinib maleate

MCLEAN, Va.--(BUSINESS WIRE)-- Zephyr AI , Inc. (“Zephyr AI”), a leader in precision medicine harnessing artificial intelligence to accelerate drug development, today announced that it has appointed Lisa Eli, PhD, as its Chief Scientific Officer. Eli brings over 20 years of experience in translational medicine and precision oncology, with deep expertise in advancing biomarker-driven clinical development. She has led integrated biomarker and diagnostic strategies across Phase 1-3 clinical trials, enabling patient selection, informing combination approaches, and supporting regulatory approvals and guideline inclusions in solid tumors. At Zephyr AI, Dr. Eli will leverage this experience to accelerate AI-powered, biomarker-driven diagnostic and clinical development of targeted therapies. “I am thrilled to join Zephyr AI and support the company's groundbreaking work in oncology discovery and drug development,” said Eli. “The power of AI combined with deeply profiled real-world data offers an immense opportunity to accelerate clinical development and bring biomarker-informed, precise therapies to point of care. I am eager to work with our industry partners to help optimize treatment and elevate the quality of care for people with cancer.” “Lisa is a key addition to Zephyr AI’s leadership team,” said Zephyr AI CEO Allen Chao, PhD. “She brings a wealth of experience advancing oncology programs from scientific discovery through clinical development and commercialization, and her leadership will energize Zephyr’s ability to apply proprietary data, AI, and machine learning to accelerate smarter drug development.” As a thought leader in precision oncology, Dr. Eli has led translational medicine teams and supported important developments in cancer treatment. Most recently, Eli founded and led Eli Precision Oncology, LLC, a consultancy where she supported clients in biomarker-driven patient stratification and clinical development strategies. Prior to that, Eli was Vice President of Translational Medicine and Diagnostics at Puma Biotechnology, where she was a key driver of the SUMMIT basket trial of neratinib (Nerlynx®) for patients with solid tumors harboring HER2 mutations. She also held senior roles at N-of-One and Monogram Biosciences, where she supported diagnostic development of HERmark®, a tissue-based assay for HER2 quantitation. In addition, Eli was an appointed member of the California Breast Cancer Research Council and currently serves as an Advisor for the SPARK Program in Translational Research at Stanford. Eli received a Ph.D. in Biochemistry from Stanford University, and completed her postdoctoral fellowship at UCSF. About Zephyr AI Zephyr AI is redefining precision medicine with AI-enabled software and enterprise-scale real-world data. By transforming fragmented clinical and biological information into actionable insights, Zephyr AI advances therapeutic development, patient stratification, and diagnostic innovation—bringing clarity to complexity and impact to patients. Zephyr AI’s solutions integrate seamlessly into existing workflows for rapid validation and clinical translation. Alongside its software models, Zephyr AI provides access to one of the world’s largest proprietary multimodal clinicogenomic datasets—enabling partners to explore populations, accelerate discovery, and improve trial success. For more information, visit zephyrai.bio . Contacts media@zephyrai.bio

Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib - a targeted tyrosine kinase inhibitor (TKI) SAN FRANCISCO, CA / ACCESS Newswire / April 8, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar") today announced that the Company has completed the company's ongoing effectiveness study of crofelemer delayed-release tablets for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Crofelemer, under the name Canalevia-CA1 , is currently conditionally approved for the sole indication of treating CID in dogs. The approval for Canalevia CA-1 will expire on December 21, 2026. "We're very pleased that enrollment has concluded for this study, which is being undertaken at veterinary oncology clinics around the US. The FDA granted renewal of the conditional approval for Canalevia-CA1 for a fifth and final year, through December 21, 2026, for the treatment of CID in dogs. In order to receive a full veterinary drug approval for the indication of CID beyond Dec. 21, 2026, Jaguar must complete and successful effectiveness study," said Dr. Michael Guy, D.V.M., M.S., Ph.D., Jaguar's Vice President of Preclinical and Nonclinical Studies. In the second quarter of 2026 Jaguar plans to submit and results of the company's effectiveness study and the positive results of a study of crofelemer delayed-release tablets for treatment of CTD in dogs receiving neratinib - a targeted tyrosine kinase inhibitor (TKI) chemotherapy agent. "The 28-day study in dogs receiving neratinib was designed to evaluate the scientific rationale for the use of crofelemer tablets in reducing the severity and incidence of diarrhea in cancer patients receiving neratinib, a targeted therapy known to cause significant diarrhea," said Dr. Guy "The study demonstrated that crofelemer dosing resulted in a 30% reduction in the incidence and severity of diarrhea in participating dogs, which was statistically significant." The results of the neratinib study were presented at the American Association for Cancer Research Virtual Annual Meeting II in June 2020 and published in the peer-reviewed journal PLOS ONE in January 2024. The study, titled Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs , was conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, Inc. and can be viewed by clicking here . Many cancer treatment agents provided to dogs are human drugs, or have the same mechanism of action as human cancer drugs, and these agents and mechanisms of action often have meaningful rates of diarrhea in dogs and humans. A report by the American Veterinary Medical Association concluded that there were approximately 90 million dogs in the US in 2025, of which Jaguar estimates more than 11 million suffer from general diarrhea each year. Data from the European Pet Food Industry Federation concluded that there were approximately 90 million dogs in Europe in 2023. Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics. About Chemotherapy-induced Diarrhea (CID) in Dogs According to the American Veterinary Medical Association, approximately 1 in 4 dogs will at some stage in their life develop cancer. Nearly half of dogs over 10 will develop cancer. 1 According to the National Cancer Institute at the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs yearly in the US. Due to the increasing number of chemotherapeutic agents, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment, 2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the US veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their canine patients' chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID. Important Safety Information About Canalevia ® -CA1 For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit napotherapeutics.com Canalevia-CA1, visit canalevia.com Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will submit an administrative NADA for crofelemer in the second quarter of 2026 that will include the results of the company's ongoing confirmatory study of crofelemer for treatment for CID in dogs and the results of the study of crofelemer for treatment of CID in dogs receiving neratinib. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 1 "Cancer in Pets." American Veterinary Medical Association, 2021, 2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398 Contact: hello@jaguar.health Jaguar-JAGX SOURCE: Jaguar Health, Inc. View the original press release on ACCESS Newswire